Advances in insulin therapy

Journal of the Pakistan Medical Association

Volumn 63, Issue 7, 2013, Pages 925-927

  Kalra, Sanjay ^a  

^a Bharti Hospital and BRIDE ^*  (India)

Author keywords

Diabetes pharmacotherapy; Insulin

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ASPART; INSULIN ASPART PLUS INSULIN DEGLUDEC; INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; LIRAGLUTIDE; LIXISENATIDE; LONG ACTING INSULIN;

ARTICLE; DIABETES MELLITUS; DRUG DELIVERY DEVICE; DRUG MECHANISM; HUMAN; INSULIN TREATMENT; PREGNANCY; RECOMBINANT DNA TECHNOLOGY; WEIGHT REDUCTION;

DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 84879285606     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. van Bon AC, Bode BW, Sert-Langeron C, Devries JH, Charpentier G. Insulin Glulisine Compared to Insulin Aspart and to Insulin Lispro Administered by Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: A Randomized Controlled Trial. Diab Technol Therap 2011; 13: 1-8.
2. Rašlová K, Bogoev M, Raz I, Leth G, Gall M-A, Hâncu N. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Research and Clinical Practice 2004; 66: 193-201.
3. Barlocco D. Insulin glulisine. Curr Opin Investig Drugs 2003; 4: 1240-1244.
4. Bolli GB, Owens DR. Insulin glargine. Lancet 2000; 356: 443-445.
5. Barlocco D. Insulin detemir. Curr Opin Investig Drugs 2003; 4: 449-454.
6. Jonassen I, Havelund S, Ribel U, et al. Insulin degludec is a new generation ultra-long acting basal insulin with a unique mechanism of protraction based on multihexamer formation [abstract]. Diabetes 2010; 59: A11.
7. Heise T, Tack CJ, Cuddihy R, Davidson J, Gouet D, Liebl A et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabetes Care 2011; 34: 669-674.
8. Kalra S, Kalra B, Kumar S. The IMPERIAL study: physicians' perceptions regarding intensification of insulin therapy. Endocrine Abstracts, 2010; 22: 298.
9. Garber AJ, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006; 8: 58-66.
10. Holst JJ, Vilsbøll T. Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings. Diabetes, Obesity and Metabolism 2013; 15: 3-14.